A Mayo Clinic-trained, board-certified radiologist and founder of Innovative Radiology in Des Moines, Dr. Tentinger leads a comprehensive imaging practice spanning mammography, MRI, CT, ultrasound, and X-ray. An early adopter of the QTI Breast Acoustic CT™ scanner, he brings hands-on clinical experience with the technology and a practicing-radiologist perspective to QT Imaging’s advisory work.
A fellowship-trained surgical oncologist and breast surgeon who completed his surgical residency at UCSF and surgical oncology fellowship at MD Anderson Cancer Center, Dr. Roseman brings more than 25 years of experiencemore than 25 years of experience and over 5,000 breast cancer patients treated, Dr. Roseman brings direct clinical authority on the real-world challenges of breast diagnosis and care.
Section Chief of Breast Imaging at USC’s Keck School of Medicine and a longtime leader in breast cancer screening research, Dr. Yamashita advises QT Imaging on clinical interpretation standards, structured reporting, and training design. Her academic and diagnostic expertise strengthens the scientific rigor behind QT Imaging’s clinical adoption strategy.
Dr. Julia Albright has more than 25 years of experience leading innovation and commercialization initiatives across medical imaging, digital health, healthcare artificial intelligence, cloud technologies, and oncology. As Chief Science Officer of QT Imaging, she leads the Company’s scientific strategy, working across research and development, engineering, clinical, and product organizations to advance quantitative breast imaging, AI-powered image analysis, clinical evidence generation, and next-generation imaging technologies.
Prior to joining QT Imaging, Dr. Albright served as Managing Director of the HIT and Enterprise Solutions Business Unit at Canon Medical Systems USA. Throughout her career, she has held senior leadership positions at GE HealthCare, Amazon Web Services, NextGen Healthcare, and CorTechs AI, where she led the development and commercialization of quantitative medical imaging software for automated image analysis.
Dr. Albright has also held product and business leadership roles at Philips, Varian Medical Systems, and Siemens Healthineers, contributing to the development and market expansion of innovative imaging, oncology, and digital health solutions. Throughout her career, Dr. Albright has been instrumental in expanding markets, developing new clinical applications, building strategic partnerships, and bringing innovative healthcare technologies from concept to commercialization. Her expertise includes quantitative imaging, AI-enabled diagnostics, healthcare data platforms, cloud-based solutions, product strategy, and evidence-based innovation.
Dr. Albright holds a Ph.D. from Humboldt University of Berlin, an MBA from Boston University’s Questrom School of Business, and a Master of Science from Heidelberg University. She also completed the Stanford LEAD Corporate Innovation Program through the Stanford Graduate School of Business.
Mr. Timm is an experienced strategist, brand builder, and go-to-market executive who most recently served as President of a $2.5 billion global portfolio of brands, fueling growth across geographic and distribution channels. Tim Boyle, CEO of Columbia Sportswear and a longtime colleague, credited Mr. Timm as having “played an integral role in our journey from a single brand with approximately $300M in sales in 1997 to a multi-brand, multi-channel business with $2.4b in sales in 2016 and more than 6,000 employees around the world,” adding that he was “a key contributor to our growth and transformation” and helped establish leadership that positioned the Mountain Hardwear brand and the company’s direct-to-consumer business for future growth.
Mr. Timm established corporate operating platforms that enabled brands to grow profitably by streamlining supply chains, reducing time to market, and reinvesting resulting savings into consumer awareness. He led a global, multi-year business transformation that cost in excess of $100 million and returned a combined $350 million, expanding gross margin and reducing operating costs while fueling brand awareness. Known as a people-focused leader, he has a track record of engaging employees and motivating teams to execute at a high level.
Mr. Timm serves as Audit Committee Chairman and Board Vice-Chairman of Umpqua Holdings Corporation (Nasdaq: UMPQ), a community bank with over $25 billion in assets. He is a past Chairman and member of the Northwestern Mutual Policy Owners’ Examining Committee, and serves on the boards of the Doernbecher Children’s Hospital Foundation and the University of Idaho School of Business and Economics Advisory Board.
Mr. Timm holds a Bachelor’s degree in Accounting from the University of Idaho, where he received the Silver and Gold Achievement and Service award. He was named CFO of the Year for Overall Public Companies by the Portland Business Journal and was a nominee for Best CFO of a Consumer Apparel, Footwear, and Textiles Company by Institutional Investor.
Mr. Misra, appointed as Chief Commercial Officer in November 2025, is responsible for driving commercial scale-up and clinical partnerships, positioning QT Imaging as a modality of choice for supplemental breast screening and biomarker-driven precision diagnostics.
A seasoned executive with three decades of progressive leadership in Radiology, Oncology and Molecular Imaging, Mr. Misra is recognized for his expertise in scaling complex businesses, leading acquisitions and integrations, and forging high-impact alliances to expand into white-space markets. He came to QT Imaging from the Company’s strategic partner, Canon Medical Systems USA (“Canon USA”), where he most recently served as Executive Senior Vice President, Chief Sales and Marketing Officer.
Prior to first joining Canon USA in 2012, Mr. Misra was Philips’ Head of Business Development and Marketing, and before that, Siemens Healthcare’s Director of Business Management. Mr. Misra has a Bachelor of Science and a Bachelor of Technology in applied physics from the University of Calcutta in India, attended the School of Business and Economic Studies at the University of Leeds in the United Kingdom, and has a certificate in negotiation from Harvard Business School in the United States.
Mr. Jennings, who was appointed as Chief Financial Officer of QT Imaging in September 2025, is responsible for operational finance, financial reporting, budgeting and strategic planning, and treasury management.
Mr. Jennings has an accomplished history of financial, operational, and strategic leadership success within the digital healthcare and high technology industries. In an executive management career that spans close to 30 years, he has led two go-public transactions, completed various private and public financings, built and managed finance teams ranging up to 100 employees, and been integrally involved in 12 business acquisitions. Mr. Jennings most recently served as Acting Chief Executive Officer and Chief Financial Officer for UpHealth, Inc., a global digital health company. His earlier experience includes executive financial roles at eHealth, Inc., a NASDAQ-listed consumer online marketplace, and MetaCreations Corporation, a NASDAQ-listed developer of visual computing and graphics software and technologies.
Prior to launching his corporate career in 1996, Mr. Jennings was an Audit Manager at Ernst & Young, LLP, and has been a Certified Public Accountant in the State of California since 1992. Mr. Jennings earned a Bachelor of Arts in Economics / Accounting from Claremont McKenna College in 1989.
My passion as a breast imager involves using safe and effective technology to diagnose breast cancer. I completed my radiology residency at Tufts Medical Center in Boston, MA in 1998 and a breast imaging fellowship at the Faulkner-Sagoff/BWH Breast Center in Boston in 1999. I spent my academic career working as a breast imager in various medical organizations including Beth Israel Deaconess Medical Center /Harvard Medical School and Brigham and Women’s Community Division. These years taught me a lot about the discipline of breast imaging and about the difficulties patients endure in their breast health journey. I learned many lessons, most importantly that patients have a say in what technologies they like and their expectations of the breast imaging experience. From the patient’s point of view, imaging should be comfortable, safe, stress-free, and results should be accurate.
With this in mind, I felt the desire to step beyond clinical work and use my experience as a breast imager to help develop a new breast imaging technology with scientists and engineers whose mission is to improve the breast imaging experience for patients, to try and offer an alternative in the current standard of care. Our performance as breast imagers is always limited by the technology available to us. This is the driving force that led me to QT Ultrasound 10 years ago as Chief Medical Officer and that’s why I’m grateful to return.
Returning to the publicly traded QT Imaging Holdings, Inc. as Chief Medical Officer, the mission of this dedicated group of professionals is clinical adoption and commercialization, as well as continued research & development for QTI as a safe, effective and cutting-edge alternative imaging modality for breast cancer diagnosis and management.
Mr. Dickson has held executive-level positions in companies from Fortune 50 to start-ups and in industries from consumer products to enterprise software. He began his career at General Electric Company, where he held strategic and operating roles on corporate staff and in the company’s $1 billion consumer electronics division. He left GE to join an early-stage company in real-time networked retail distribution, where he was a key player in the company’s IPO. Mr. Dickson then assumed the role of COO for Pine Company, a privately held market research and data management company in Santa Monica, CA, where he repositioned the company as an early player in the customer relationship management (CRM) space. This led to an offer from Draper, Fisher Jurvetson, a Silicon Valley-based venture capital firm, to serve as President and CEO for one of the fund’s portfolio companies.
Mr. Dickson then assumed the position of VP of The Brenner Group, where he led the firm’s interim CEO practice as well as serving as a “parachute CEO” for multiple Silicon Valley-based venture-funded technology companies. These involved firms in the data warehousing, software development, document management, and medical industries, including Armus Corporation, which focused on clinical outcomes for small- and large-scale healthcare providers, and Vital Transport, Inc., which developed an end-to-end system for organ transplant tracking and delivery.
In 2003, Mr. Dickson returned to the East Coast, where he was recruited by Palo Alto Investors to take over as President and CEO of Best Cellars, Inc., an innovative wine retailer with locations from Massachusetts to Texas. During his tenure, the company doubled its sales and created a significant internet business. This led to the company’s acquisition by the $9 billion publicly traded A&P grocery chain in 2007.
More recently, Mr. Dickson has held executive, consulting, and board positions in the wine industry and currently maintains an independent consulting practice focusing on strategic analysis and M&A activities across multiple industries. Mr. Dickson holds a B.S. degree in Marketing and Journalism from Boston University and an M.B.A. degree from Harvard’s Graduate School of Business Administration.
Zeev Weiner is a professor in obstetrics and gynecology dedicating most of his academic and research career to introduce ultrasound and Doppler ultrasound for women health. From 2014, he is the Chairman of the Division of Obstetrics and Gynecology at Rambam Medical Center and full professor at the faculty of medicine, The Technion Institute of Technology, Haifa, Israel. His sub specialty is Maternal Fetal Medicine and Ultrasound in Obstetrics and Gynecology. His previous clinical position were Director of the Maternal Fetal Medicine Unit at Lutheran Medical Center, Brooklyn, NY, (from 2003 to 2005) and Director of Ultrasound in Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel (from 2005 to 2014).
Professor Zeev Weiner combines clinical activity with research. He has published 200 peer review articles in medical journals, presented many of his research works in international meetings, he has been a reviewer in most prestigious medical journals in obstetrics and gynecology, and an editor in the Life journal. His main field of research has been ultrasound and Doppler ultrasound in Obstetrics and Gynecology. During the nineties, he made a great contribution while introducing color Doppler ultrasound for screening and detecting ovarian cancer, supported by The Israeli Cancer Association. The results of his studies were published in gynecology and ultrasound journals. His studies contributed to the introduction of transvaginal ultrasound and color Doppler ultrasound for the detection of pelvic cancer.
Continuing his research on ultrasound and Doppler ultrasound, Professor Weiner contributed to the detection for fetal anomalies and fetal cardiac circulation. He contributed to the development and the application of the very high-end ultrasound and Doppler ultrasound equipment. For many years, Professor Weiner has been teaching and demonstrating in national and international conferences and seminars the most advanced ultrasound and Doppler ultrasound equipment and modalities. Professor Weiner holds his MD degree from Sackler Faculty of Medicine, Tel Aviv University (1986) and his MHA from Recanati Business school, Tel Aviv University (2012).
Dr. Klock has served as the Chief Executive Officer of QT Imaging since 2014 and as a Director and Founder of QT Imaging since 2011. Prior to serving in these positions with QT Imaging, Dr. Klock was involved in the start-up of five medical companies, including as Co-Founder and President of BioMarin Pharmaceutical, Inc., which successfully commercialized five FDA drugs; and Scientific Founder and Vice President of Research of Glycomed, Inc., which was acquired by Ligand Pharmaceuticals, Inc.
Dr. Klock also personally brought to market a novel cancer treatment, the first rapid AIDS test, comprehensive tests for detecting metabolic diseases in children, and several drugs for treating pediatric genetic conditions. Dr. Klock has authored over 70 peer reviewed medical and scientific publications and has been granted eight patents.
Since 1980, Jim has been serving the global financial services industry. 21 of those years with Accenture where he was instrumental in creating and leading their global financial services business. The last 20 years spread between being CEO of a technology start-up, global head of Financial Services for Cap Gemini, global head of Financial Services Consulting for Cisco and as a Managing Partner of a private equity fund focused on creating and incubating enterprise class analytics software companies. He has worked with over 75 start-ups in the last 10 years ranging from fintech, payment tech, big data, platforms, to name a few.
He is Founder and Managing Director of Sky D Ventures. A venture fund and advisory services firm. They focus primarily in seed rounds in fintech, emerging technologies, commerce platforms, to name a few. In addition, they provide advisory services to incumbents and disrupters alike in financial services, to private equity and VC’s in FinTech and to technology companies serving the financial services industry.
Jim’s industry tenure has been primarily focused on serving global financial services clients. His functional expertise spans consumer, wealth management, commercial, financial markets, mortgage, payments and business models. His geographic experience is balanced across North America, EU, Asia and Emerging Markets. Jim’s work with clients covers large-scale solution development and implementation, business and technology strategy development, and new venture creation and operation. He has an abundance of experience in creating and scaling strategic partnerships and ecosystems. Jim is a well-recognized thought leader on several topics. He regularly hosts and moderates small to large executive conferences and visits to the Silicon Valley. He is a frequent speaker at industry conferences on the topics of Enabling Commerce and New Models for Profitable Growth in Global Financial Services. He also serves on the Boards of both public and private companies.
Dr. Katz is a philanthropist, entrepreneur, High-Tech executive, and since 2017 is the Founding Managing Partner and Executive Chairman of GigCapital Global (www.GigCapitalGlobal.com), a serial issuer of Private-to-Public Equity (PPE) entities, also known as Special Purpose Acquisition Companies (SPACs). Since inception in September of 2017 GigCapital Global (GIG) has issued and completed initial public offerings of six PPE entities, and completed combinations and taking public of five entities; using the PPE platforms; GIG1 combined in November 2019 with Kaleyra (NYSE KLR), which was sold to Tata Communications in November 2023, GIG2 combined with UpHealth Holding in June 2021 (NYSE UPH), GIG3 combined in May 2021 with Lightning eMotors (NYSE ZEV), GIG4 combined with BigBear in December 2021 (NYSE BBAI), and GIG5 combined with QT-Imaging (NASDAQ QTI) in February 2023. Dr. Katz is a veteran of more than 35 years of activity with small and middle-size High-Tech companies as founder, chairman of the board of directors, executive and CEO, and as angle and-later stage investor.
Dr. Katz chairs and participates in many boards of directors of private and public High-Tech companies, as well as non-for-profit organizations and, among others, is a member of the board of directors of the New York Philharmonic orchestra. Prior to founding GigCapital Global enterprise in 2017, Dr. Katz bootstrapped GigPeak / GigOptix (NYSE American GIG) in 2007 and led the organization as the chairman of the Board and CEO from the inception and until its sale in 2017 to IDT International (NYSE IDTI).
Prior to funding GigOptix, Dr. Katz has held CEO and board member positions with privately held companies, including Intransa Inc. and Equator Inc., and earlier he served in several executive positions following his tenure as a member of the technical staff in AT&T Bell Laboratories, Murray Hill, New Jersey in the 80’s and early 90s. Dr. Katz is a graduate of the 1976 class of the Israeli Naval Academy and holds a B.Sc. and Ph.D. in Semiconductors Materials from the Technion (Israel Institute of Technology). Dr. Katz is a serial entrepreneur, holds many U.S. and international patents, has published more than 300 technical papers and is the editor of a number of technical books.
Dr. Bilal Malik has over ten years of experience in research, development, and translation of medical devices, both in academia and industry. He is an expert in leading and directing efforts in image and data science and has a track record of successfully leading innovation for medical imaging products, directing research strategy, and navigating FDA pathways. As Chief Science Officer of QT Imaging, Dr. Malik led the R&D efforts behind the industry’s first-in-class transmission ultrasound breast scanner, from prototyping to FDA clearance and commercialization. As an imaging scientist at Genentech, he provides imaging scientific leadership in late-stage clinical trials in oncology.
Dr. Malik received his BS degree in engineering sciences from GIK Institute, Pakistan, and MS and PhD degrees in electrical and biomedical engineering from Texas A&M University. He has published over 30 peer-reviewed papers and over 60 conference presentations (h-index: 20). He is also a member of the US National Institutes of Health (NIH) medical imaging study section (ISB-10), reviewing grant submissions by small businesses in the area of medical imaging.
For over three decades Mr. Pirshafiey has developed products and businesses for domestic and multinational firms. Mr. Pirshafiey’s creativity, innovative problem-solving skills, and entrepreneurial mindset have provided professional, technical, and business solutions to many start-ups and mature companies.
In 2014, Mr. Pirshafiey joined the QT Imaging startup company, where he led the technology group in production design and commercialization of the novel breast imaging modality, while further developing the technology for other imaging applications, including diagnostic imaging of human extremities, joints, infant imaging, and imaging internal organs. He led the technology team members—building a focused team of mechanical, electrical, software, science, and image reconstruction scientists. Additionally, Mr. Pirshafiey established the breast imaging device manufacturing team.
Mr. Pirshafiey has previously founded and managed two companies with the mission to provide sustainable practices to industries such as medical devices, automotive, aerospace, high-tech, consumer products, and robotics (brief client list: Johnson & Johnson, Siemens, Edwards Life Sciences, Autoliv, TRW). Mr. Pirshafiey has 18 inventions filed with the US patent office, holds a Bachelor of Science in Aeronautical Engineering, and an MBA with specialization in Entrepreneurship.
On a personal note, Mr. Pirshafiey is a Multiengine Instrument Rated Commercial pilot, who enjoys sharing his passion of flying by being part of the Angle Flight West team. A group of volunteers and pilots, who provide free medical transportation to people in need.
Mr. Steve Choate, appointed as Chief Operations Officer at QT Imaging in March 2024, is responsible for managing the operations organization, ensuring quality, and fostering collaboration with internal, domestic, and international manufacturing partners.
With over 30 years of experience across diverse industries such as aerospace, space, semiconductor, and telecommunications, Mr. Choate has held key leadership positions and brings extensive expertise as a production operations leader with a focus on overseeing manufacturing activities, product development, and production releases. He served as the VP of Operations at GigOptix, where he oversaw manufacturing on a global scale, Director of Engineering at Teledyne Microwave Solutions, and as an account manager at Endwave, handling various customers in the RF milliwave transceivers space and managing offshore engineering teams.
Mr. Choate began his career at Lockheed Martin, progressing from a design engineer to a role in the program office, where he managed engineering development programs for remote satellite tracking stations. His academic background includes a Bachelor of Science in Mechanical Engineering from San Jose State University and a Master of Science in Mechanical Engineering from Stanford University.
Mr. Budagov has served as the Chief Financial Officer of QT Imaging since December 2023. Prior to joining QT Imaging, Mr. Budagov served as an independent consultant at various accounting firms, through which he has been providing consulting services to public and private clients since 2022. Mr. Budagov previously provided financial consulting services to private and public companies while at Acilon Consulting LLC from 2017 until 2022, serving as acting revenue director at Natera, Inc., a public biotech company, acting finance director at Kodiak Sciences, Inc., a public life science company, and a senior manager of more than five IPO projects for clients in the medical device, life science, and biotech industries.
Immediately prior, Mr. Budagov worked at The Siegfried Group, where he was a contractor at Ernst and Young from 2013 to 2016, and advisor to management teams of public companies regarding audit processes, internal controls, and commercial contracts in 2017. Mr. Budagov also has four years of accounting experience, having served as senior accountant at regional public accounting firms. He earned his Bachelor of Science degree in accounting from George Mason University in Fairfax, VA and has been a Certified Public Accountant in the State of Virginia since 2013 and a Certified Internal Auditor since 2017.
Dr. Dinu has spent approximately 25 years in international executive positions within the TMT industry working for privately held start-ups, middle-cap companies, and large enterprises. In these roles, Dr. Dinu has been instrumental in launching and accelerating entities, building teams, large-scale fund raising, developing key alliances and technology partnerships, M&A activities, business development, financial management, global operations and sales and marketing. Dr. Dinu is managing partner of GigCapital Global, a serial issuer of Private-to-Public Equity (PPE) entities, also known as Special Purpose Acquisition Companies (SPACs). Since inception in September of 2017 GigCapital Global (GIG) has issued and completed initial public offerings of six PPE entities, and completed combinations and taking public of five entities; using the PPE platforms; GIG1 combined in November 2019 with Kaleyra (NYSE: KLR), which was sold to Tata Communications in November 2023, GIG2 combined with UpHealth Holding in June 2021 (NYSE: UPH), GIG3 combined in May 2021 with Lightning eMotors (NYSE ZEV), GIG4 combined with BigBear in December 2021 (NYSE: BBAI), and GIG5 combined with QT-Imaging (NASDAQ: QTI) in February 2023.
Dr. Dinu serves as Chair of the Compliance Committee, and member of the Audit Committee and Compensation Committee of UpHealth, Inc. since March 2019, and as a member of the Board of Directors and a member of the Audit Committee of BigBear.ai. Dr. Dinu serves on the board of directors of NY Philharmonic since May 2023.
Dr. Dinu has held leadership positions at several other companies, including at IDT’s Optical Interconnects Division (as vice president and general manager), GigPeak (as executive vice president, chief operation officer, executive vice president of Global Sales and Marketing, and senior vice president of Global Sales and Marketing), Brazil-Photonics (as a director) and Lumera Corporation (as vice president of engineering). Dr. Dinu holds a B.Sc. in Physics and Ph.D. in Solid State Condensed Matter Physics from the University of Bucharest, and an Executive-M.B.A. from Stanford University. Dr. Dinu has an Audit Committee Certificate, Compensation Committee Certificate, as well as a Corporate Director Certificate from Harvard Business School, Executive Education Program.
